Nov 6, 2016
Kim Walpole, co-founder and CEO, Trials.ai an EvoNexus portfolio company that is replacing paper based clinical trial systems with digital access to the hundreds of data points from participants, leveraging artificial intelligence to allow for more efficient trials, and providing transparency for patients and researchers.
@evonexus